Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRV-3279 in healthy subjects
NCT03955666Phase 1Completed
- Sponsor
- Provention Bio
- Start
- Aug 2019
- Primary completion
- Dec 2019
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PRV-3279 in systemic lupus erythematosus (SLE) (2 cohorts), sponsored by Provention Bio. Primary endpoint: Incidence and severity of treatment-emergent adverse events at 85 days. Started Aug 2019; status: completed.
02
Drugs
PRV-3279
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03955666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955666.